Glenmark Pharmaceuticals has significantly expanded its presence in the “High Latin America” region, which includes Mexico, Colombia, Ecuador, Peru, Central America, and the Caribbean, over the past four years. The company’s growth in this region has been driven by innovation, product launches, and operational efficiency. In Mexico, Glenmark has nearly tripled its revenue, doubled its workforce, and expanded its sales force in recent years. The company attributes its success to its strategic use of data analytics, which enables it to identify high-growth therapeutic niches and make informed investment decisions.
Glenmark is also leveraging digitalization and telemedicine to accelerate research and adoption of new therapies. The company has a strong portfolio in respiratory care, dermatology, and oncology, and is focusing on launching innovative products in these areas. In Mexico, Glenmark is a market leader in oral solids and nasal sprays for allergic rhinitis, and has recently launched a new product that reached the number three position in nasal spray combinations within 10 months.
The company’s growth strategy also involves forming strategic alliances and co-development projects. Glenmark has established partnerships with local and regional laboratories to commercialize its molecules, and has also entered into collaborations with major pharmaceutical companies such as AstraZeneca. These partnerships allow Glenmark to expand its therapeutic coverage and maintain a robust pipeline of new products.
Over the next three to five years, Glenmark plans to launch a range of new products in respiratory, dermatology, and oncology. The company is committed to continuing to innovate and launch differentiated products that provide physicians with expanded therapeutic options and improve patient outcomes. In terms of digitalization, Mexico is seen as a strategic hub with enormous potential, offering greater business certainty and scalability than other Latin American countries.
Regulatory trends in Latin America are also influencing access to specialized therapies, with agencies increasingly adopting accelerated approval pathways and recognizing approvals from high-surveillance markets. Glenmark is preparing for these trends by digitalizing its processes and improving its regulatory capabilities. The company’s advice to other pharmaceutical companies operating in Mexico is to identify market niches, continuous innovation, and align investment decisions with long-term objectives. Overall, Glenmark’s position in Latin America is strong, and the company is well-placed to continue growing and expanding its presence in the region.